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Abstract: OBJECTIVES We developed the first German evidence- and consensus-based clinical guideline
on diagnosis, treatment, and follow-up of germ cell tumours (GCT) of the testes in adult patients. We
present the guideline content in 2 separate publications. The present second part summarizes therec-
ommendations for the treatment of advanced disease stages and for the management of follow-up and
late effects. MATERIALS AND METHODS An interdisciplinary panel of 42 experts including 1 patient
representative developed the guideline content. Clinical recommendations and statements were based on
scientific evidence and expert consensus. For this purpose, evidence tables for several review questions,
which were based on systematic literature searches (last search in March 2018), were provided. Thirty-one
experts, who were entitled to vote, rated the final clinical recommendations and statements. RESULTS
Here we present the treatment recommendations separately for patients with metastatic seminoma and
non-seminomatous GCT (stages IIA/B and IIC/III), for restaging and treatment of residual masses,
and for relapsed and refractory disease stages. The recommendations also cover extragonadal and sex
cord/stromal tumours, the management of follow-up and toxicity, quality-of-life aspects, palliative care,
and supportive therapy. CONCLUSION Physicians and other medical service providers who are involved
in the diagnostics, treatment, and follow-up of GCT (all stages, outpatient and inpatient care as well as
rehabilitation) are the users of the present guideline. The guideline also comprises quality indicators for
measuring the implementation of the guideline recommendations in routine clinical care; these data will
be presented in a future publication.
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Abstract
Objectives: We developed the first German evidence- and 
consensus-based clinical guideline on diagnosis, treatment, 
and follow-up of germ cell tumours (GCT) of the testes in 
adult patients. We present the guideline content in 2 sepa-
rate publications. The present second part summarizes the 
recommendations for the treatment of advanced disease 
stages and for the management of follow-up and late effects. 
Materials and Methods: An interdisciplinary panel of 42 ex-
perts including 1 patient representative developed the 
guideline content. Clinical recommendations and state-
ments were based on scientific evidence and expert consen-
sus. For this purpose, evidence tables for several review 
questions, which were based on systematic literature search-
es (last search in March 2018), were provided. Thirty-one ex-
perts, who were entitled to vote, rated the final clinical rec-
ommendations and statements. Results: Here we present 
the treatment recommendations separately for patients 
with metastatic seminoma and non-seminomatous GCT 
(stages IIA/B and IIC/III), for restaging and treatment of re-
sidual masses, and for relapsed and refractory disease stag-
es. The recommendations also cover extragonadal and sex 
cord/stromal tumours, the management of follow-up and 
toxicity, quality-of-life aspects, palliative care, and support-
ive therapy. Conclusion: Physicians and other medical ser-
vice providers who are involved in the diagnostics, treat-
ment, and follow-up of GCT (all stages, outpatient and inpa-
tient care as well as rehabilitation) are the users of the present 
guideline. The guideline also comprises quality indicators for 
measuring the implementation of the guideline recommen-
dations in routine clinical care; these data will be presented 
in a future publication. © 2021 The Author(s)
Published by S. Karger AG, Basel
Background
We are presenting the main content of the new Ger-
man clinical practice guideline in a publication series; 
part I covers the following chapters: epidemiology, clas-
sification systems, diagnostics, prognosis, and treatment 
recommendations for the localized stages [1]. Here, part 
II covers the recommendations for the metastatic stages, 
for recurrent and refractory disease, and for follow-up, 
toxicity management, quality of life, palliative care, and 
supportive therapy.
The online supplementary German S3 guideline (see 
www.karger.com/doi/10.1159/000511245 for all online 
suppl. material) is freely available for download in the 
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The objectives of this guideline have been described 
previously in part I [1].
Methods
The methods of this guideline have been described 
previously in part I [1].
Results
Chapter 8: Primary and First-Line Therapy 
(Continued)
See part I for the previous recommendations [1]. See 
also Tables 1–3 for the dosages and applications. 
Metastatic Germ Cell Tumours of the Testes
Stages IIA/B
19 In patients with cSIIA seminoma either radiotherapy 
or chemotherapy with 3 cycles of BEP (bleomycin, eto-
poside, and cisplatin; alternatively, 4 cycles of EP [eto-
poside and cisplatin] if bleomycin is contraindicated) 
is recommended. The lack of prospective randomized 
controlled trials for the direct comparison of radiother-
apy versus chemotherapy for seminoma cSIIA/B does 
not allow a valid statement regarding the superiority or 
equivalence in oncological efficacy of either therapy. 
We recommend informing the patient about the ad-
vantages and disadvantages of both treatment options 
(grade A: very low quality of the evidence) [e2–e6].
20 It is recommended that patients with cSIIB seminoma 
receive chemotherapy with 3 cycles of BEP or, in case 
of contraindications to bleomycin, 4 cycles of EP. Al-
ternatively, radiotherapy can be performed. The lack 
of prospective randomized controlled trials for the di-
rect comparison of radiotherapy versus chemotherapy 
for seminoma cSIIB does not allow a valid statement 
regarding the superiority or equivalence in oncologi-
cal efficacy of either therapy. We recommend inform-
ing the patient about the advantages and disadvantag-
es of both treatment options (grade A: very low quality 
of the evidence) [e2, e4, e6].
21 Radiotherapy with 30 Gy (total dose) is recommended 
for patients with cSIIA seminoma and radiotherapy 
with 36 Gy (total dose) is recommended in stage cSIIB 
seminoma (A, 2b).
22 We recommend performing a control imaging with an 
abdominal/pelvic CT scan 2–3 months after radio-
therapy. It is recommended to proceed equally after 
chemotherapy. The result of this examination is also 
the starting point for follow-up care (expert consen-
sus).
23 In non-seminomatous cSIIA/B GCT we recommend 
treatment according to the International Germ Cell 
Cancer Collaborative Group (IGCCCG) with chemo-
therapy (3–4 cycles of BEP), and in case of a residual 
tumour we recommend treatment with residual tu-
mour resection (RTR). Exception: in GCT initially 
classified as 100% teratoma in the orchiectomy speci-
men without a marker increase, retroperitoneal lymph 
node dissection (RPLND) is recommended (A, 2b) [e7, 
e8].
24 Patients with serum tumour marker-negative non-
seminomatous cSIIA GCT should be monitored first 
(serum tumour marker monitoring, repeat imaging af-
Table 1. BEP regimen
Substance Dosage Application 
Cisplatin 20 mg/m2 (1 h i.v.) Days 1–5 
Etoposide 75–100 mg/m2 (1 h i.v.) Days 1–5 
Bleomycin 30 mg (bolus i.v.) Days 1, 8, and 
15 
Repeat on day 22.
Table 2. EP regimen
Substance Dosage Application
Etoposide 100 mg/m2 (1 h i.v.) Days 1–5 
Cisplatin 20 mg/m2 (1 h i.v.) Days 1–5 
Repeat on day 22.
Table 3. VIP regimen
Substance Dosage Application
Cisplatin 20 mg/m2 (1 h i.v.) Days 1–5 
Etoposide 100 mg/m2 (1 h i.v.) Days 1–5 
Ifosfamide 1,200 mg/m2 (2 h i.v.) Days 1–5 
Repeat on day 22.
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ter 6–8 weeks) or, alternatively, a diagnostic RPLND 
should be performed (B, 2b) [e7, e8].
25 In patients with serum tumour marker-negative cSIIA 
non-seminomatous GCT and after primary RPLND 
with pN1 findings (PS IIA) in the R0 status, active sur-
veillance is recommended (A, 1b). Alternatively, 2 cy-
cles of EP can be administered if there is no pure tera-
toma (0) [e9–e12, e7].
26 Patients after primary RPLND in serum tumour mark-
er-negative cSIIA non-seminomatous GCT with pN2 
findings (PS IIB) should be monitored in the R0 status 
(B, 1b). Alternatively, if there is no pure teratoma, 2 
cycles of BEP or EP can be administered (0) [e13, e9, 
e10, e12, e7].
Stages IIC/III
27 The standard regimen of polychemotherapy for meta-
static disease is BEP (statement, 1b) [e9].
28 Growth factors should be used in BEP as a secondary 
prophylaxis in case of neutropenic fever in the previ-
ous cycle (B, 1b) [e9, e14, e15].
29 When applying the VIP regimen (etoposide, ifos-
famide, cisplatin), we recommend using a myeloid 
growth factor (G-CSF) as a primary prophylaxis (A, 
1b) [e14, e16].
30 In patients with metastatic IIC/III stage GCT of the 
good prognosis group according to the IGCCCG, we 
recommend polychemotherapy with 3 cycles of BEP 
with application of cisplatin and etoposide for 5 days 
(A, 1b) [e17–e19, e15].
31 In patients with acute life-threatening metastatic go-
nadal GCT, we recommend primarily administering 
chemotherapy without a prior orchiectomy (expert 
consensus).
32 After completion of chemotherapy in patients with go-
nadal GCT, we recommend performing an orchiec-
tomy of the initially affected testis if this has been post-
poned due to acute life-threatening advanced meta-
static disease at diagnosis (A, 4) [e20–e23].
33 In patients with stage IIC/III metastatic seminoma and 
a good prognosis we recommend 3 cycles of BEP che-
motherapy (A, 1a) [e24].
34 In patients with stage IIC/III metastatic seminoma and 
a good prognosis we recommend 4 cycles of EP if bleo-
mycin is contraindicated (A, 4) [e25, e26].
35 In patients with metastatic seminoma and an interme-
diate prognosis, we recommend 4 cycles of BEP (A, 1b).
36 In patients with metastatic seminoma and an interme-
diate prognosis, we recommend 4 cycles of VIP if bleo-
mycin is contraindicated (A, 1b) [e27].
37 In patients with metastatic non-seminomatous GCT 
stage IIC/III and a good prognosis, we recommend 3 
cycles of BEP (A, 1b) [e18].
38 Patients with metastatic non-seminomatous GCT 
stage IIC/III and a good prognosis should receive 4 
cycles of EP if contraindications to bleomycin exist (B, 
1b) [e18, e28].
39 In patients with metastatic non-seminomatous GCT 
and an intermediate prognosis we recommend 4 cycles 
of BEP (A, 1b) [e27].
40 In patients with metastatic non-seminomatous GCT 
and an intermediate prognosis, we recommend 4 cy-
cles of VIP if contraindications to bleomycin exist (A, 
1b) [e27].
41 In patients with metastatic non-seminomatous GCT 
and a poor prognosis, we recommend 4 cycles of BEP 
(A, 1b) [e9].
42 In patients with metastatic non-seminomatous GCT 
and a poor prognosis, we recommend 4 cycles of VIP 
if contraindications to bleomycin exist (A, 1b) [e29].
43 In patients with primary mediastinal disease, bone 
and/or brain metastases, and/or an inadequate serum 
tumour marker decline, we recommend considering 
treatment intensification (A, 1b–4) [e30–e34].
44 It is recommended that the evaluation of treatment in-
tensification be performed at a centre with proven ex-
perience (expert consensus).
45 We do not recommend general intensification of first-
line therapy in favour of a high-dose chemotherapy 
with autologous stem cell transplantation for the un-
selected group of all GCT patients with a poor progno-
sis (A, 1b) [e35, e36].
46 To assess the response to therapy, we recommend 
analysis of the serum tumour marker decline after 1, 
or at the latest after 2, cycles of standard-dose chemo-
therapy (A, 1b) [e35].
47 In patients with an inadequate serum tumour marker 
decline after 1 or 2 cycles of cisplatin-based first-line 
therapy, intensification of chemotherapy should be 
considered on an individual basis (grade B: moderate 
quality of the evidence) [e37].
48 When chemotherapy is intensified by means of pri-
mary high-dose therapy, sequential therapy should be 
performed with 3 cycles of high-dose VIP, each fol-
lowed by autologous stem cell transplantation (B, 1b) 
[e38, e36].
See also Table 4 [e36].
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49 In patients with brain metastases at the initial diagno-
sis, we recommend either referral of patients to a GCT 
centre with proven experience or consultation at a cen-
tre with proven expertise prior to therapy (expert con-
sensus).
50 In patients with brain metastases at the initial diagno-
sis, we recommend 4 cycles of chemotherapy (BEP, 
VIP) according to the IGCCCG poor prognosis group 
(A, 2b). Alternatively, primary therapy intensification 
can be performed (0) [e30, e39, e40, e33].
51 Due to insufficient data, no reliable statement regard-
ing the benefit of post-chemotherapeutic radiotherapy 
and/or resection (in case of residual brain metasta-
sis*). Any additional treatment should be decided 
upon based on interdisciplinary discussion on an indi-
vidual basis (statement, 2b) [e30, e39, e40, e15, e33].
52 Due to documented long-term toxicity of whole brain 
radiotherapy of the neurocranium, stereotactic radio-
therapy should be sought if possible (B, 2b) [e39, e40, 
e33].
53 In patients with bone metastases at the initial diagno-
sis, we recommend 4 cycles of chemotherapy (BEP, 
VIP) according to the IGCCCG intermediate progno-
sis (seminoma) and poor prognosis (non-seminoma-
tous GCT) group (A, 4) [e34].
54 We recommend that patients with bone metastases at 
the initial diagnosis be referred to a centre with proven 
experience, or that such a centre be consulted prior to 
therapy (expert consensus).
55 Primary high-dose chemotherapy is no standard ap-
proach (in patients with bone metastases*), but it 
should be evaluated on an individual basis and consid-
ered where appropriate (B, 2b) [e32].
56 We recommend considering subsequent local therapy 
of bone metastases following chemotherapy on an in-
dividual basis (resection or radiation if technically 
possible). Due to insufficient data, a reliable statement 
regarding the benefit of post-chemotherapeutic radio-
therapy and/or resection of residual bone lesions can-
not be provided (A, 4) [e34, e41].
57 We recommend performing decompression of tu-
mour-induced hydronephrosis before initiating che-
motherapy (expert consensus).
58 In patients with renal impairment, we do not recom-
mend general replacement of cisplatin by carboplatin. 
The individual treatment decision should be made af-
ter consulting a centre with proven experience or a sec-
ond-opinion online portal such as eKonsil Urologie 
(Hodentumor) in Germany (https://hodentumor.
zweitmeinung-online.de/) (expert consensus).
59 Carboplatin-based chemotherapy is associated with 
increased recurrence rates and increased tumour-re-
lated mortality and it should therefore be restricted to 
justifiable individual cases (statement, 1b) [e42–e44].
60 We recommend that patients with active HIV disease 
receive sufficient antiretroviral therapy before initiat-
ing chemotherapy. It is recommended that the choice 
of antiretroviral therapy consider possible interactions 
with the cytostatic agents applied (expert consensus).
61 Active HIV disease is not a contraindication to stage-
matched chemotherapy. Primary prophylactic admin-
istration of G-CSF (unless it is with VIP therapy) and 
antibiotic prophylaxis are not required (expert consen-
sus).
62 In patients with active HIV disease*, we recommend 
determining the CD4 cell count before each chemo-
therapy cycle. With CD4 counts < 200/μL, antibiotic 
prophylaxis with cotrimoxazole should be adminis-
tered (expert consensus).
63 Patients with advanced/metastatic GCT disease should 
preferably be treated by multidisciplinary teams at 
centres with proven experience in order to maximize 
the chance of cure and prevent treatment-associated 
adverse events by avoiding overtreatment (expert con-
sensus).
* Additional information due to the abbreviated pre-
sentation of the text.
Restaging and Treatment of Residual Tumour Disease
64 Immediate chemotherapy without a prior orchiecto-
my should only be initiated in patients with life-threat-
ening symptoms and high serum tumour markers for 
AFP and β-hCG (B, 4) [e45].
65 FDG-PET/CT can be applied in seminoma patients 
with normal or normalized serum tumour markers 
Table 4. High-dose VIP regimen (after e36)
PEB 
Cisplatin 20 mg/m2 (1 h i.v.) Days 1–5 
Etoposide 75mg/m2 (30 min to 1 h i.v.) Days 1–5 
Ifosfamide 1,200 mg/m2 (2 h i.v.) Days 1–5 
High-dose PEB
Cisplatin 20 mg/m2 (1 h i.v.) Days 1–5 
Etoposide 300 mg/m2 (30 min to 1 h i.v.) Days 1–5 
Ifosfamide 2,400 mg/m2 (2 h i.v.) Days 1–5 
High-dose VIP: stem cell re-infusion on day 7.
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who have residual disease larger than 3 cm in diameter 
after completion of therapy (0, 1a). The CT as part of 
the FDG-PET/CT scan should preferably be per-
formed as a contrast-enhanced CT (expert consensus) 
[e46, e47].
66 We recommend performing FDG-PET/CT for the 
evaluation of serum tumour marker-negative residual 
tumours in seminoma patients not earlier than 6 weeks 
after completion of chemotherapy (expert consensus).
67 In case of positive metabolic activity in FDG-PET/CT, 
intensified follow-up (CT and serum tumour marker 
control) should be performed (expert consensus).
68 After completion of first-line therapy of a metastatic 
seminoma, RTR should not be performed (B, 1b) [e48].
69 Restaging after first-line chemotherapy should not in-
clude an FDG-PET/CT scan in patients with non-sem-
inomatous GCT (B, 2b) [e49, e50].
70 In patients with non-seminomatous GCT, we recom-
mend resection of residual retroperitoneal and pulmo-
nary tumours > 1 cm that persist after completion of 
first-line chemotherapy and achievement of serum tu-
mour marker normalization. It is recommended that 
the management of residual tumours at other sites be 
decided upon individually (A, 2b) [e51].
71 Surgical removal of residual pulmonary metastases > 1 
cm is recommended. It is recommended that bilateral 
thoracic RTR be decided on interdisciplinarily when 
the histology of the resection of the first side is avail-
able. It is recommended that the resection be carried 
out using a parenchyma-saving approach with the op-
portunity for digital palpation (A, 4) [e52, e53].
72 It is recommended that RTR be performed in centres 
with proven experience with the opportunity for inter-
disciplinary surgical care (e.g., liver resections, vascu-
lar grafting, spinal neurosurgery) (A, 2b) [e54–e56].
73 Retroperitoneal RTR should preferably be performed 
using a nerve-sparing technique (B, 4). It is recom-
mended that the template of RTR be defined depend-
ing on the initial tumour site (A) [e57–e59].
74 Tumour resection only (so-called lumpectomy) should 
not be performed (B, 2b) [e57, e60–e63].
75 In patients with R0 resection upon RTR, follow-up is 
recommended. In case of vital tumour cells, an indi-
vidual approach is recommended, depending on the 
histology, the postoperative serum tumour markers, 
and morbidity, since a benefit for survival after adju-
vant chemotherapy is currently unclear (expert con-
sensus).
76 In patients after salvage chemotherapy of a retroperi-
toneal non-seminomatous GCT relapse, retroperito-
neal RTR should be performed even in tumours < 1 cm 
if tumour markers have normalized (B, 4) [e64].
Chapter 9: Recurrent and Refractory Tumours
Recurrences after the Initial Stage I
1 In patients with recurrent seminoma after initial cSI, 
we recommend classification and treatment according 
to the extent of disease based on IGCCCG criteria (ex-
pert consensus).
2 In patients with a recurrent non-seminomatous GCT 
after the initial stage I, we recommend classification 
and treatment based on IGCCCG criteria. Only in pa-
tients with recurrence earlier than 6 months after ad-
juvant therapy with 2 cycles of BEP should alternative 
chemotherapy regimens be considered (expert consen-
sus).
Recurrence after Chemotherapy for Metastatic Disease
3 We recommend classification of patients with recur-
rence after first-line chemotherapy for metastatic dis-
ease according to the risk classification of the Interna-
tional Prognostic Factors Study Group (IPFSG) (ex-
pert consensus).
4 Patients with recurrence after cisplatin-based combi-
nation chemotherapy due to primary metastatic dis-
ease can receive conventional-dose chemotherapy ac-
cording to the TIP (paclitaxel, ifosfamide, cisplatin) or 
VIP regimen (0, 2b) [e65].
5 Patients after cisplatin-based combination chemo-
therapy for primary metastatic disease should receive 
primary salvage chemotherapy using sequential high-
dose chemotherapy with 3 cycles of HD-CE (carbopla-
tin + etoposide) and autologous stem cell support (B, 
1b). Alternatively, patients with relapse following cis-
platin-based combination chemotherapy for primary 
metastatic disease can receive conventional-dose che-
motherapy according to the TIP or VIP regimen (0) 
[e66–e68].
6 Patients (with recurrence*) after cisplatin-based com-
bination chemotherapy for primary metastatic disease 
should be included in clinical trials if possible (expert 
consensus).
7 In non-seminomatous GCT patients undergoing sal-
vage chemotherapy for a retroperitoneal relapse, RTR 
should be performed even in residual tumours < 1 cm 
after normalization of tumour markers (B, 4) [e64].
* Additional information due to the abbreviated pre-
sentation of the text.
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Patients with Bone Metastases at Recurrence
8 In patients with recurrent bone metastases, we recom-
mend performing a systemic combination chemother-
apy (expert consensus).
9 Since bone metastases at recurrence represent a high-
risk situation, the patient should preferentially be 
treated with high-dose chemotherapy (expert consen-
sus).
10 After systemic therapy of recurrent bone metastases, 
additional local therapy (resection or radiotherapy) 
should always be evaluated. Comparative prospective 
data are not available for these two therapy options 
(expert consensus).
11 For vitality assessment after systemic chemotherapy, a 
biopsy can be considered prior to local therapy in pa-
tients with extensive bone metastases (expert consen-
sus).
Cerebral Metastases in Recurrence
12 In patients with cerebral metastases at relapse, high-
dose chemotherapy should be administered (B, 2b). 
Retrospective studies indicate a survival benefit from 
consolidation radiotherapy. In case of incomplete re-
mission, it is recommended that radiotherapy be per-
formed additionally (A, 2b). In case of complete remis-
sion of cerebral metastases in imaging after salvage 
chemotherapy, the situation is unclear and additive 
radiotherapy should be considered individually (B, 2b) 
[e33].
13 In patients with solitary residuals after salvage chemo-
therapy, we recommend performing stereotactic radi-
ation and/or neurosurgical resection of brain metasta-
ses (expert consensus).
14 In patients with multiple residuals after salvage che-
motherapy, it is recommended that radiotherapy of 
the neurocranium be performed (expert consensus).
Late Relapses
15 In patients with marker-negative late recurrence and 
in whom complete resectability seems possible, we rec-
ommend performing a primary surgical resection (A, 
2b) [e69, e70].
16 Patients with a non-resectable late recurrence have a 
poor prognosis. These patients should primarily re-
ceive chemotherapy (either conventional or high-dose 
chemotherapy) and secondary resection should be 
considered (B, 4) [e71].
Refractory and Multiply Recurrent GCT
17 In patients with recurrence or progressive relapse after 
multiple chemotherapy regimens, we recommend of-
fering a combination chemotherapy with gemcitabine 
and oxaliplatin +/– paclitaxel (GOP). Following a re-
sponse to therapy with GOP, the resection of all re-
sidual tumours is recommended (A, 4) [e72–e77].
Special Cases
18 In patients with growing teratoma syndrome, we rec-
ommend complete surgical resection (A, 4) [e78–e80].
19 In cSI patients with malignant somatic transforma-
tion, we recommend RPLND (A, 4) [e81, e82].
20 In patients with metastatic disease and components of 
malignant somatic transformation, we recommend 
performing a GCT-based chemotherapy first, followed 
by RPLND (expert consensus).
21 In patients with malignant somatic transformation re-
lapsing after GCT therapy, we recommend choosing a 
chemotherapy regimen based on the histology of the 
somatic malignancy (A, 4) [e83, e81, e82].
Chapter 10: GCT Not Related to GCNIS and Sex 
Cord/Stromal Tumours
Spermatocytic Tumour
1 The spermatocytic tumour – formerly spermatocytic 
seminoma – is a very rare tumour that requires differ-
entiation from classical seminoma. The diagnostic 
measures do not differ from those applied in gonadal 
GCT (expert consensus).
2 The pure spermatocytic tumour limited to the testes is 
a tumour with a good prognosis, which is sufficiently 
treated by orchiectomy and surveillance (expert con-
sensus).
3 The presence of sarcomatous components in a sper-
matocytic tumour indicates a highly malignant trans-
formation of the tumour with a poor prognosis and 
requires a multimodal therapy concept with chemo-
therapy, RTR, and possibly radiation therapy. The se-
quence of the individual steps needs to be determined 
individually for each patient (expert consensus).
4 It is recommended that sarcomatous components of 
the spermatocytic tumour be ruled out upon histolog-
ical evaluation (expert consensus).
Extragonadal GCT
5 Ninety-five percent of all male adult GCT originate in 
the testicles; 5% are of primarily extragonadal origin 
(expert consensus).
Kliesch et al.Urol Int 2021;105:181–191188
DOI: 10.1159/000511245
6 We recommend confirming the diagnosis of extrago-
nadal GCT histologically only in case of an ambiguous 
constellation of serum tumour markers (expert con-
sensus).
7 The determination of the serum tumour markers 
(AFP, β-hCG, LDH) in extragonadal GCT is recom-
mended for confirmation of the diagnosis, for correct 
classification according to the IGCCCG, and for mon-
itoring of the treatment responses (expert consensus).
8 All patients with mediastinal non-seminomatous ex-
tragonadal GCT are classified as belonging to the poor 
prognosis group (stage III) according to the IGCCCG. 
Due to their very poor prognosis, high-dose chemo-
therapy should be chosen primarily. Performance of a 
radical RTR should yield a good response (B, 2b). We 
recommend the involvement of centres with proven 
experience in the therapy (A, 2b) [e84].
9 We recommend to classify patients with retroperito-
neal non-seminomatous extragonadal GCT depend-
ing on their serum tumour marker levels according to 
the IGCCCG classification (A, 2b) [e84].
10 We recommend performing therapy of extragonadal 
GCT in analogy to metastatic gonadal GCT according 
to the histology and the corresponding IGCCCG clas-
sification. Centres with proven experience should be 
involved in the therapy (expert consensus).
Sex Cord/Stromal Tumours
11 In patients suspected of having a Leydig cell tumour or 
a Sertoli cell tumour, we recommend determining the 
serum tumour markers (AFP, β-hCG, LDH) as well as 
testosterone, LH, and FSH for endocrinological evalu-
ation (expert consensus).
12 We recommend establishing intraoperatively the his-
tological diagnosis by frozen section. We recommend 
performing organ-preserving surgery in small tu-
mours (< 2 cm) if no malignancy criteria are present 
(A, 3) [e85].
13 Malignant gonadal stroma tumours of Leydig cell or 
Sertoli cell origin should be treated with radical orchi-
ectomy (expert consensus).
14 If histological examination of Leydig cell or Sertoli cell 
tumours reveals criteria for the malignancy, RPLND 
should be performed in stage I patients (B, 2b) [e54, 
e86, e87].
15 In malignant Leydig cell or Sertoli cell tumours we rec-
ommend performing an RPLND in stage II patients 
(expert consensus).
Chapter 11: Follow-Up after Curative Therapy
There is no international consensus on follow-up rec-
ommendations for patients with GCT in full remission 
after curative therapy. A number of publications address 
follow-up schedules.
1 MRI of the abdomen/pelvis should replace CT of the 
abdomen/pelvis in the follow-up care of patients with 
GCT if performed at centres with proven experience 
to reduce radiation exposure. Experienced radiologists 
are required for the interpretation of results (expert 
consensus).
The recommendations given in Tables 5–11 are based 
on the following publications and are separately illustrat-
ed for the different patient groups [e88–e90]. 
Chapter 12: Toxicity, Management of Toxicity, and 
Supportive Measures
1 Acute toxicity occurring during therapy should be re-
corded systematically and appropriate therapeutic 
measures should be taken (expert consensus).
2 In the follow-up care, the examination and, if neces-
sary, the treatment of therapy-related late sequelae and 
long-term toxicity play a central role in addition to the 
search for disease recurrence (expert consensus).
3 After radiation or chemotherapy, fertility impairment 
is common in GCT patients compared to the normal 
male population and can persist as a long-term sequela 
after completion of treatment (expert consensus).
4 GCT patients are at risk of clinically relevant hypogo-
nadism. Therefore, we recommend asking the patient 
about related symptoms and determining serum levels 
of testosterone and LH as part of the diagnostic mea-
sures during therapy and follow-up (expert consensus).
5 In patients with hypogonadism, therapy follows the 
recommendations for testosterone replacement thera-
py (expert consensus).
6 During cisplatin-containing chemotherapy for meta-
static GCT, thromboembolism prophylaxis with low-
molecular-weight heparin should be used to reduce 
the risk of thromboembolic events in patients (B, 2b) 
[e91].
Chapter 13: Quality of Life and Rehabilitation
1 In patients with GCT, quality-of-life data should be 
collected before and during treatment (expert consen-
sus).
2 The EORTC QLQ-TC 26 questionnaire for quality-of-
life assessment, which was specifically developed for 
patients with GCT, is available in the German lan-
guage (statement, 3b) [e92].
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3 Depending on individual needs, it is recommended 
that all patients eligible for rehabilitation be offered 
post-treatment rehabilitation (expert consensus).
4 It is recommended that the rehabilitation of patients 
with GCT be carried out in rehabilitation clinics offer-
ing age-specific services with oncological competence 
and by using multimodal therapy concepts (expert 
consensus).
Table 5. Group 1: patients with local therapy in the retroperitoneum




Seminoma I 20 Gy 3–5 Years 1–3 
Seminoma IIA 30 Gy 5–10 Years 1–4 
Seminoma IIB 36 Gy 10–15 Years 1–4 
Non-seminomatous GCT IIA/B 3× PEB + RTR 2–5 Years 1–3
Non-seminomatous GCT IIC/III (good prognosis) 3× PEB + RTR 11–18 Years 1–4 
Table 6. Follow-up schedule for group 1: patients with local therapy in the retroperitoneum 
Time, years 1 2 3 4 5 >6 
Follow-up schedule (visits), n/year 4 4 2 2 2 1 
CT of the abdomen (frequency), months 12 24 – – – –
Ultrasound of the abdomen (frequency), months 6 18 36 48 60 –
Ultrasound of the testes, n/year 1 1 1 1 1 1
Chest X-ray (frequency), months 6+12 18+24 36 48 60 –
Physical examination including blood pressure/BMI/
markers, n 
4 4 2 2 2 1
Extended lab tests including hormones/lipids, n/year 1 1 1 1 1 1
Check for late toxicitya, n/year At least 1 At least 1 At least 1 At least 1 At least 1 At least 1
Seminoma CS I, IIa/b + radiotherapy, non-seminomatous GCT IIa/b + 3x PEB + RTR, non-seminomatous GCT IIc/III good + 3× 
PEB + RTR, including CT of the pelvis in seminoma stage I after radiotherapy. In non-seminomatous GCT with initial supradiaphragmal 
involvement (stage III) instead of chest X-ray: chest CT at 6, 12, and 24 months. a Intervals need to be adapted to the respective therapy.
Table 7. Group 2: Patients without local therapy in the retroperitoneum




Seminoma I Carbo monotherapy 3–5 Years 1–3b
Seminomaa IIB/IIC/III (good prognosis) 3× PEB/4 EP 11–18 Years 1–4
Non-seminomatous GCT I high risk 1× PEB 
(or 2× PEB according to the 
former recommendation) 
3–5 Years 1–5
Non-seminomatous GCT IIA/B/IIC/III (good prognosis) 3× PEB 8–18 Years 1–3
a Complete remission or residual tumour <3 or >3 cm, PET negative. b 15% of seminoma recurrences still occur after the 3rd follow-
up year.
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Table 8. Follow-up schedule for group 2: patients without local therapy in the retroperitoneum
Time, years 1 2 3 4 5 >6 
Follow-up schedule (visits), n/year 4 4 2 2 2 1 
CT of the abdomen (frequency)a, months 6+12 24 – – – –
Ultrasound of the abdomen (frequency), months (6b) 18 36 48 60 –
Ultrasound of the testes, n/year 1 1 1 1 1 1
Chest X-ray (frequency), months 6+12 18+24 36 48 60 –
Physical examination of blood pressure/BMI/markers, n 4 4 2 2 2 1
Extended lab tests including hormones/lipids, n/year 1 1 1 1 1 1
Check for late toxicityb, n/year At least 1 At least 1 At least 1 At least 1 At least 1 At least 1
Seminoma I + 1× carbo, seminoma IIA/IIB/C, III good + 3× PEB/4 EP, non-seminomatous GCT I high + 2× PEB, non-seminomatous 
GCT IIA-C, III good +3× PEB. No CT in month 6 for seminoma and non-seminomatous GCT stage I after chemotherapy, but ultrasound 
of the abdomen. In non-seminomatous GCT with initial supradiaphragmal involvement (stage III) instead of a chest X-ray: chest CT at 
6, 12, and 24 months. a 15% of recurrences in stage I seminoma still occur after 3 years, so that follow-up with CT of the abdomen may 
have to be adjusted. b Intervals must be adapted to the respective therapy.
Table 9. Follow-up schedule for group 3: patients under active surveillance
Group Histology/stage Therapy Recurrence rate, % Period of time
3Aa Seminoma I None 12–31 Years 1 and 2
3Bb Non-seminomatous GCT (low risk) None 14–22 Years 1 and 2
a Seminoma stage I. b Non-seminomatous GCT stage I without vascular invasion of the primary tumor.
Table 10. Follow-up schedule for group 3A: seminoma stage I under active surveillance
Time, years 1 2 3 4 5 6–10 
Follow-up schedule (visits), n/year 4 4 2 2 2 1 
CT of the abdomen (frequency), months 6+12 18+24 – – – –
Ultrasound of the abdomen (frequency), months 3+9 15+21 30+36 48 60 –
Ultrasound of the testes, n/year 1 1 1 1 1 1
Chest X-ray (frequency), months 6+12 18+24 36 48 60 –
Clinical examination of blood pressure/BMI/markers, n 4 4 2 2 2 1 
Extended lab tests including hormones/lipids, n/year 1 1 1 1 1
Table 11. Follow-up schedule for group 3B: nonseminomatous GCT stage I low-risk tumours under active surveillance
Time, years 1 2 3 4 5 6–10 
Follow-up schedule (visits), n/year 6 6 4 2 2 1 
CT of the abdomen (frequency), months 4+12 – – – – –
Ultrasound of the abdomen (frequency), months – 24 36 48 60 –
Ultrasound of the testes, n/year 1 1 1 1 1 1
Chest X-ray (frequency), months 6+12 18+24 30+36 48 60 –
Clinical examination including blood pressure/BMI/markers, n 6 6 4 2 2 1 
Extended lab tests including hormones/lipids, n/year 1 1 1 1 1 1
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Chapter 14: Palliative Care, Psycho-Oncology, and 
Supportive Therapy
1 If incurable disease becomes obvious, we recommend 
informing the patient and, when required, his or her 
relatives, at an early stage about palliative care options. 
Access to these should be facilitated (expert consensus).
2 Low-threshold psychosocial counselling, support, and 
treatment should be available to all affected persons 
and their relatives in every phase of the disease, as well 
as in the long term (expert consensus).
Key Messages of Part II
 − The lack of prospective randomized controlled trials 
for the direct comparison of radiotherapy versus che-
motherapy for seminoma cSIIA/B does not allow a val-
id statement regarding the superiority or equivalence 
of either therapy with respect to oncological efficacy.
 − In patients with acute life-threatening disease with 
metastatic gonadal GCT in stages IIC/III, we recom-
mended administerimng chemotherapy upfront and 
postponing orchiectomy of the initially affected testis 
until completion of the chemotherapy. 
 − We recommend analysis of the serum tumour markers 
after 1, or at the latest after 2, cycles of standard-dose 
chemotherapy.
 − Particular attention and careful consideration are re-
quired in patients with contraindications to bleomy-
cin, with brain and bone metastases, with renal impair-
ment, or with active HIV infection.
 − In patients with primary mediastinal disease, bone 
and/or brain metastases, and/or an inadequate serum 
tumour marker decline, we recommend evaluating 
treatment intensification.
 − We recommend classifying and treating patients with 
relapsing seminoma or non-seminomatous GCT after 
the initial stage I based on their recurrent stage by 
analogy to primary metastatic seminoma/non-semi-
nomatous GCT according to IGCCCG criteria.
 − There is no international consensus on follow-up rec-
ommendations for patients with GCT in full remission 
after curative therapy.
 − In patients with a serum tumour marker-negative late 
recurrence, we recommend performing a primary sur-
gical resection in cases where complete resectability is 
technically feasible.
 − In patients with relapse or progression after multiple 
chemotherapy, we recommend offering a combination 
chemotherapy with gemcitabine and oxaliplatin +/– pa-
clitaxel (GOP). Following a response to therapy with 
GOP, resection of all residual tumours is recommended.
 − Acute toxicity occurring during therapy should be re-
corded systematically and appropriate therapeutic 
measures should be taken.
 − In the follow-up care, the examination, and, if neces-
sary, the treatment of therapy-related late sequelae and 
long-term toxicity play a central role in addition to the 
search for disease recurrence. 
 − In patients with GCT, quality-of-life data should be 
collected before and during treatment. 
 − Research gaps in the context of this guideline were par-
ticularly evident for healthcare research and with re-
spect to risk factors for disease incidence. In addition, 
the statements related to the poor prognosis group are 
based on limited data. The evaluation of follow-up 
schedules by long-term studies is also still pending.
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